↓ Skip to main content

Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction

Overview of attention for article published in Diabetology & Metabolic Syndrome, September 2017
Altmetric Badge

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction
Published in
Diabetology & Metabolic Syndrome, September 2017
DOI 10.1186/s13098-017-0272-7
Pubmed ID
Authors

Yan-Rong Li, Sung-Sheng Tsai, Yu-Sheng Lin, Chang-Min Chung, Szu-Tah Chen, Jui-Hung Sun, Miaw-Jene Liou, Tien-Hsing Chen

Abstract

Evidences support the benefits of moderate- to high-intensity statins for patients with acute myocardial infarction (AMI) except for those with type 2 diabetes mellitus (T2DM) on dialysis after AMI. This study was aimed to investigate the safety and efficacy of secondary prevention of cardiovascular diseases using moderate- to high-intensity statins in T2DM patients on dialysis after AMI. A simulated prospective cohort study was conducted between January 1st, 2001 and December 31st, 2013 utilizing data from the Taiwan National Health Insurance Research Database. A total of 882 patients with T2DM on dialysis after AMI were selected as the study cohort. Cardiovascular efficacy and safety of moderate- to high-intensity statins were evaluated by comparing outcomes of 441 subjects receiving statins after AMI to 441 matched subjects not receiving statins after AMI. The primary composite outcome included cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke. The Kaplan-Meier event rate for the primary composite outcomes at 8 years was 30.2% (133 patients) in the statin group compared with 25.2% (111 patients) in the non-statin group (hazard ratio [HR], .98; 95% confidence interval [CI] .76-1.27). Significantly lower risks of non-fatal ischemic stroke (HR, .58; 95% CI .35-.98) and all-cause mortality (HR, .70; 95% CI .59-.84) were found in the statin group. In T2DM patients on dialysis after AMI, the use of moderate- to high-intensity statins has neutral effects on composite cardiovascular events but may reduce risks of non-fatal ischemic stroke and all-cause mortality.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 19%
Student > Bachelor 3 12%
Student > Ph. D. Student 3 12%
Student > Doctoral Student 2 8%
Lecturer 2 8%
Other 4 15%
Unknown 7 27%
Readers by discipline Count As %
Medicine and Dentistry 8 31%
Nursing and Health Professions 3 12%
Neuroscience 2 8%
Psychology 2 8%
Economics, Econometrics and Finance 1 4%
Other 1 4%
Unknown 9 35%